BLT future gets bleaker and bleaker - may explain recent selling
http://www.fiercepharma.com/story/m...ombo-it-preps-battle-gilead-abbvie/2016-01-29
Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie
January 29, 2016 | By Carly Helfand
Industry watchers have long been speculating on how Merck would take on heavyweights Gilead ($GILD) and AbbVie ($ABBV) when it priced its new hep C regimen. And now, they have their answer: Undercut them. Big-time.
Add to My Watchlist
What is My Watchlist?